The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 2, 2009, Pages 155-160

  Angelis, Konstantinopoulos ^b   Konstantinos, Giannitsas ^b   Anastasios, Athanasopoulos ^b   Dionisios, Spathas ^c   Petros, Perimenis ^a,b  

^a UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Endothelial function; Erectile dysfunction; Molecular markers; Sildenafil

Indexed keywords

BIOLOGICAL MARKER; CYCLIC GMP; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; MOLECULAR MARKER; NITRIC OXIDE; SILDENAFIL; THROMBOMODULIN; VON WILLEBRAND FACTOR; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PENIS ERECTION; PLASMA; PROSPECTIVE STUDY; TREATMENT DURATION; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; CYCLIC GMP; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES;

EID: 65649148693     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802678211     Document Type: Article

References (28)

1. Brookes ST, Link CL, Donovan JL, McKinlay JB. Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health Survey. J Urol 2008;179:250-255 (Pubitemid 350216754)
2. Bortolotti A, Parazzini F, Colli E, Landoni M. The epidemiology of erectile dysfunction and its risk factors. Int J Androl 1997;20(6):323-334 (Pubitemid 28156095)
3. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294(23):2996-3002 • An interesting paper showing the significant increase in the risk for future cardiovascular effects in men with erectile dysfunction. (Pubitemid 41817661)
4. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the 'tip of the iceberg' of a systemic vascular disorder? Eur Urol 2003;44(3):352-354
5. Chong AY, Blann AD, Lip GY. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM 2003;96 (4):253-67 •• A very interesting review of endothelial function, its assessment and association with cardiovascular disease.
6. Lue TF. Erectile dysfunction. N Engl J Med 2000;342(24):1802-1813 (Pubitemid 30390241)
7. Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995;74(3):247-253
8. Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004;43(2):179-184 (Pubitemid 38201141)
9. Yavuzgil O, Altay B, Zoghi M, et al. Endothelial function in patients with vasculogenic erectile dysfunction. Int J Cardiol 2005;103(1):19-26 (Pubitemid 41074599)
10. Kaya C, Uslu Z, Karaman I. Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res 2006;18(1):55-60
11. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 2006;27(22):2640-2648 (Pubitemid 44729862)
12. Giugliano F, Esposito K, Di Palo C, et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 2004;27(7):665-669 (Pubitemid 39359830)
13. Bocchio M, Desideri G, Scarpelli P, et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 2004;171(4):1601-1604 (Pubitemid 38365430)
14. Wierzbicki AS, Solomon H, Lumb PJ, et al. Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis 2006;185(2):421-425 (Pubitemid 43306759)
15. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005;96(3):257-280 (Pubitemid 41097665)
16. Desouza C, Parulkar A, Lumpkin D, et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002;25(8):1336-1339 (Pubitemid 41071142)
17. Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47(2):214-220 (Pubitemid 40126979)
18. Aversa A, Greco E, Bruzziches R, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007;19(2):200-207 (Pubitemid 46340840)
19. Kukreja RC, Salloum F, Das A, et al. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol 2005;42(5-6):219-232 (Pubitemid 40726325)
20. Becker AJ, Uckert S, Stief CG, et al. Systemic and cavernous plasma levels of endothelin (1-21) during different penile conditions in healthy males and patients with erectile dysfunction. World J Urol 2001;19(4):267-271
21. El Melegy NT, Ali ME, Awad EM. Plasma levels of endothelin-1, angiotensin II, nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction. BJU Int 2005;96(7):1079-1086 (Pubitemid 41531418)
22. Kim NN, Dhir V, Azadzoi KM, et al. Pilot study of the endothelin-A receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction. J Androl 2002;23(1):76-83
23. Proietti M, Aversa A, Letizia C, et al. Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 2007;34(8):1712-1717 (Pubitemid 47267615)
24. Aversa A, Vitale C, Volterrani M, et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 2008;25(1):37-44
25. Rossi R, Nuzzo A, Lattanzi A, et al. Sildenafil improves endothelial function in patients with pulmonary hypertension. Pulm Pharmacol Ther 2008;21(1):172-177
26. Hatzichristou D, Gambla M, Rubio-Aurioles E, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008;25(2):138-146 (Pubitemid 351297651)
27. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39(2):257-265 (Pubitemid 34084631)
28. Carson CC 3rd. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 2005;96 (12B):37M-41M